Related by context. All words. (Click for frequent words.) 72 recurrent metastatic 71 bladder ovarian 71 ovarian endometrial 70 BRCA deficient 70 hormone receptor negative 70 invasive lobular 70 HER2 positive breast 69 resistant hormone refractory 69 metastatic colorectal 69 endometrial breast 69 Her2 positive 69 ovarian breast 69 underwent surgical resection 69 whose tumors overexpress 69 ErbB2 positive 69 LHRH receptor positive 69 castration resistant hormone refractory 68 pancreatic lung 68 Menopausal hormone therapy 68 squamous cell lung cancer 68 invasive lobular carcinoma 68 unresectable tumors 68 Estrogen receptor positive 67 advanced HER2 positive 67 T1c 67 non resectable metastatic 67 anthracycline taxane 67 leukemia multiple myeloma 67 BRAF mutant 67 melanoma ovarian 67 nonmetastatic 67 operable breast cancer 67 Prednisone Against Refractory 67 invasive ductal 67 nonmelanoma 67 lymphomas leukemias 67 brain metastases originating 67 KRAS mutations occur 67 nonsmall cell lung cancer 66 BRCA1 mutation carriers 66 deCODE ProstateCancer TM 66 hormonally sensitive 66 ovarian pancreatic 66 metastatic malignant 66 intrahepatic bile duct 66 metastatic bladder 66 locoregional recurrence 66 Hodgkin lymphoma HL 66 pancreatic prostate 66 metastatic gastric 66 ductal carcinomas 66 breast pancreatic 66 TTF Therapy 66 underwent resection 66 situ LCIS 66 Papillary 66 oral squamous cell 66 lung esophageal 66 drug Treanda 66 untreated metastatic melanoma 66 hepatocellular carcinoma liver 65 mutated K ras 65 refractory gastrointestinal stromal 65 Folfox 65 epithelial ovarian 65 untreated metastatic pancreatic 65 allogeneic HSCT 65 recurrent epithelial ovarian 65 lobular cancer 65 lung ovary 65 lung pancreatic 65 CYT# potent vascular disrupting 65 papillary renal cell carcinoma 65 thromboembolisms 65 metastatic renal cell 65 prostate ovarian 65 Arimidex anastrozole 65 AGTR1 65 carcinoma HCC 65 Squamous cell 65 castrate resistant 65 Bevacizumab Avastin 65 breast uterine 65 basal cell skin 65 pancreatic colon 65 MAGE A3 ASCI 65 deCODE BreastCancer 65 Colon polyps 64 Adjuvant chemotherapy 64 bladder prostate 64 renal cell carcinomas 64 K ras mutations 64 relapsed MM 64 faulty BRCA genes 64 stage IIIb IV 64 dysplastic lesions caused 64 atypical hyperplasia 64 non mutated KRAS 64 MGd 64 testicular germ cell 64 acid phosphatase PAP 64 taxane refractory 64 histologic subtype 64 HER2 positive metastatic 64 taxane chemotherapy administered 64 Endometrial 64 cetuximab Erbitux 64 advanced adenoma 64 atypical ductal hyperplasia 64 Xelox 64 metastatic pancreatic 64 untreated metastatic colorectal 64 Tesmilifene 64 pegylated liposomal doxorubicin 64 Roche Herceptin 64 BRCA1 BRCA2 64 promoter hypermethylation 64 oral clodronate 64 recurrent glioblastoma multiforme 64 gastrointestinal stromal 64 Uterine cancer 64 skeletal metastases 64 gynecologic malignancy 64 haematologic 64 cervix uteri 64 premalignant lesion 64 basal cell carcinoma squamous 64 resectable pancreatic cancer 64 HER2 positive cancers 64 breast endometrial 64 noninvasive outpatient 64 cervical breast 64 lymphoid malignancies 64 ovarian colon 64 benign noncancerous 64 metastatic HER2 negative 64 ovarian prostate 63 efaproxiral 63 KRAS oncogene 63 gene BRCA2 63 pediatric acute lymphoblastic 63 progesterone receptor negative 63 thyroid carcinoma 63 precancerous condition 63 refractory metastatic 63 adjuvant cisplatin 63 gefitinib Iressa 63 advanced adenomas 63 endometrial ovarian 63 anastrazole 63 pelvic malignancies 63 dasatinib Sprycel 63 Tykerb lapatinib 63 paclitaxel Taxol R 63 medically inoperable 63 finasteride Proscar 63 pT2 63 evaluating tivozanib 63 chemotherapy cisplatin 63 Medullary thyroid cancer 63 fallopian tube carcinoma 63 tumors GIST 63 PLX STROKE targeting 63 Thalomid ® 63 metastatic renal 63 NSCLC tumors 63 endometrial hyperplasia 63 colorectal ovarian 63 hormone receptor status 63 PRESEPT study 63 pancreatic adenocarcinoma 63 Hormone Refractory Prostate Cancer 63 deep venous thromboses 63 malignant ascites 63 approved incretin mimetic 63 smoldering myeloma 63 cervical lymph node 63 nodal metastasis 63 cisplatin resistant 63 PSMA ADC 63 localized renal 63 paclitaxel cisplatin 63 mutated KRAS 63 cause mesothelioma asbestosis 63 detecting precancerous 63 ovary uterus 63 Peginterferon alfa 2b 63 serous ovarian cancer 63 endometrial cancers 63 ovarian uterine 63 goserelin 63 metastatic carcinoma 63 biochemical relapse 63 recurrent ovarian 63 kidney urologic 63 ZACTIMA 63 Solazed 63 thalidomide Thalomid 63 humanised monoclonal antibody 63 Ph + acute lymphoblastic 63 ovarian lung 63 sarcomatoid 63 FUSILEV enhances 63 colorectal bladder 62 tested eribulin 62 epithelial tumors 62 patients receiving myelosuppressive 62 recurrent NSCLC 62 densest breasts 62 underwent prostate biopsy 62 myelodysplastic myeloproliferative diseases 62 gastric cardia 62 BCG refractory 62 deCODE AF TM 62 ELACYT 62 tumor histology 62 colorectal carcinoma 62 brivanib 62 HER2 positivity 62 Basal Cell 62 diagnostic biomarker 62 cyclophosphamide methotrexate 62 complete cytogenetic response 62 Ixempra 62 radiation chemoradiation 62 Temodar ® 62 cytoreduction 62 debulking surgery 62 advanced epithelial ovarian 62 pancreatic colorectal 62 KRAS mutant 62 NMIBC 62 HNSCC 62 Renal Cell Carcinoma RCC 62 Cholangiocarcinoma 62 pancreas esophagus 62 colorectal lung 62 Acute myelogenous leukemia 62 corticosteroid dexamethasone 62 KRAS mutated 62 Combination REOLYSIN R 62 Waldenstrom macroglobulinemia 62 pancreatic bladder 62 ovarian cervical 62 PENNVAX ™ B 62 ® lenalidomide 62 Gemzar gemcitabine 62 Surgical resection 62 osteosarcomas 62 perineural invasion 62 HER2 positive metastatic breast 62 Adenomas 62 biliary tract cancer 62 cervical prostate 62 invasive carcinoma 62 acute myeloid 62 systemic ALCL 62 metastatic hormone refractory 62 gastrointestinal stromal tumors GISTs 62 follicular Non Hodgkin 62 histological subtypes 62 ductal breast cancer 62 receiving XGEVA 62 Achieves Primary Endpoint 62 bile duct cancers 62 HGPIN 62 undergone radical prostatectomy 62 taxane therapy 62 oral deforolimus 62 ipsilateral breast 62 Bezielle 62 HER2 expression 62 luteinizing hormone releasing 62 essential thrombocythemia ET 62 breast ovary 62 PF # [002] 62 BRAF mutated 62 Leukemias 62 refractory chronic lymphocytic 61 metachronous 61 infliximab etanercept 61 neovasculature 61 hormonally responsive 61 gastric corpus 61 SPORE grant 61 lenalidomide Revlimid R 61 Stage IIB 61 HER2 overexpression 61 Basal cell 61 antiretroviral naïve 61 colon ovarian 61 cisplatin gemcitabine 61 histologically confirmed 61 Oncotype 61 Nexavar sorafenib 61 atypical lobular hyperplasia 61 BCIRG 61 NSABP C 61 Gnant consults 61 metastatic HER2 positive 61 colorectal adenoma 61 Chronic lymphocytic leukemia CLL 61 HER2 negative 61 mL/min/#.# m 2 61 Anaplastic 61 breast carcinoma 61 demonstrated antitumor activity 61 hyaluronidase enzyme 61 methylation markers 61 pheochromocytomas 61 PTK# 61 colorectum 61 chemoresistant 61 advanced pancreatic neuroendocrine 61 colon rectum breast 61 endometrial carcinoma 61 LungAlert TM 61 contralateral breast 61 leiomyomas 61 haematologic malignancies 61 FOLFOX6 61 progressive metastatic prostate 61 adjuvant radiotherapy 61 PROLARIS 61 commercialize deforolimus 61 GVAX Immunotherapy 61 ixabepilone 61 Carcinoid tumors 61 Platinum Resistant Ovarian 61 histological subtype 61 node metastases 61 PARP inhibition 61 unresectable locally advanced 61 including eniluracil ADH 61 humanized interleukin 6 61 Velcade bortezomib 61 Ribavirin causes 61 LymphoStat B belimumab 61 Amgen Neulasta ® 61 BRAF gene mutations 61 Aflibercept 61 sunitinib Sutent 61 metastatic ovarian cancer 61 surgically resectable 61 trastuzumab DM1 61 CIN2 + 61 colorectal pancreatic 61 endocrine responsive 61 Accelerated Partial Breast Irradiation 61 overexpress HER2 61 Glaxo Tykerb 61 R abatacept 61 Acute myeloid leukemia 61 drug figitumumab 61 Adjuvant Treatment 61 completely resected 61 prostate adenocarcinoma 61 Myelodysplastic syndromes MDS 61 benign nodules 61 antisense inhibitors 61 OVARIAN 61 Ovary removal 61 Flu Cy 61 grade squamous intraepithelial 61 lung bronchus 61 trial evaluating PRX# 61 metastatic androgen independent 61 AML MDS 61 Vidaza ® 61 LSE ASM 61 Human papillomavirus 61 achieved CCyR 61 mouse xenograft models 61 pertuzumab 61 precursor lesions 61 Acute myeloid leukemia AML 61 GSTP1 61 alpha folate receptor 61 ascites fluid 61 Peptide YY 61 vaginal lesions 61 adenomatous 61 nonproliferative 61 infliximab monotherapy 61 benign prostatic hyperplasia enlarged 61 humanized therapeutic 61 epoetin alpha 61 squamous non 61 protein tyrosine phosphatase 1B 61 previously untreated follicular 61 thetreatment 61 intra arterial chemotherapy 61 neuroendocrine cancers 60 ovarian carcinoma 60 chemosensitizer 60 Hepatocellular 60 bilateral oophorectomy 60 adenocarcinomas 60 stage IIIB IV 60 adalimumab Humira 60 Degarelix 60 Philadelphia Chromosome Positive 60 Troxatyl 60 neoplasias 60 Epigenomics proprietary 60 Sudhir Agrawal D.Phil 60 Hycamtin ® 60 fallopian tube cancers 60 abnormal p# 60 myelogenous leukemia 60 radiosensitivity 60 basal cell carcinoma BCC 60 anal lesions 60 GVAX ® 60 syngeneic 60 pCR 60 reduce serum phosphate 60 systemic anaplastic large 60 glutamic acid decarboxylase 60 OMP #R# 60 advanced medullary thyroid 60 BRCA2 mutation carriers 60 oesophageal adenocarcinoma 60 advanced malignant hepatic 60 hypermethylated 60 PANVAC VF 60 Temodar temozolomide 60 nondiabetic patients 60 TNFerade TM 60 pulmonary metastases 60 HER2 Positive 60 Gliadel Wafer 60 lymphatic cancers 60 metaglidasen 60 aplastic anemia AA 60 antihormonal 60 EGFR TKI 60 p# biomarker 60 Zorbtive TM 60 Anthracycline 60 mda 7 60 PROSTVAC VF 60 CTAP# Capsules 60 radiation sensitizer 60 antiangiogenic agent 60 MCF7 60 Naive Patients 60 receptor inhibiting monoclonal 60 biliary cancer 60 leukaemias 60 metastatic colorectal carcinoma 60 salpingo oophorectomy 60 cediranib 60 HER2 positive tumors 60 advanced metastatic prostate 60 metaplasia 60 renal cortical 60 radiochemotherapy 60 mutated BRAF gene 60 peritoneal cancer 60 surgical debulking 60 differentiated thyroid 60 alkylating agent 60 cervical ovarian 60 benign neoplasms 60 hPAM4 60 pituitary adenomas 60 relapsed acute lymphoblastic 60 hypervascular tumors 60 polycythemia vera essential thrombocythemia 60 tongue mouth pharynx 60 FGFR2 gene 60 neoadjuvant setting 60 5 fluorouracil leucovorin 60 antibody MAb 60 microtubule inhibitor 60 Li Fraumeni 60 anti PlGF 60 precancerous cervical 60 R sorafenib tablets 60 Vidaza azacitidine 60 bladder carcinoma 60 Cancer Incidence Mortality 60 Atypical Hemolytic Uremic Syndrome 60 alpha1 antitrypsin deficiency 60 Group RTOG 60 Vicinium TM 60 selectively inhibited 60 Amgen Neulasta R 60 rhabdoid 60 PCNSL 60 HRPC ovarian cancer 60 uterine ovarian 60 colorectal gastric 60 human IgG1 monoclonal 60 Kinoid 60 pretransplant 60 esophagogastric junction 60 Endometrial cancer 60 Pfizer Camptosar 60 Gleevec resistant 60 adjuvant tamoxifen 60 anti EGFR antibody 60 flutamide 60 taxane resistant 60 hA# 60 PSADT 60 prostate carcinoma 60 premalignant lesions 60 uterine cervical 60 ductal adenocarcinoma 60 Vidaza R 60 Tocosol Paclitaxel 60 TNF blocker therapy 60 Brain metastases 60 BRAF V#E mutation 60 benign prostatic hypertrophy 60 bladder cancers 60 zoledronic acid Reclast 60 paclitaxel Taxol ® 60 prostate cancer CaP 60 fibrocystic disease 60 investigational immunotherapy 60 AMEVIVE 60 HyperAcute 60 Camptosar ® 60 Myelodysplasia 60 INSPIRE Trial Phase III 60 intraepithelial neoplasia 60 pediatric pontine glioma 60 malignant neoplasm 60 pretreatment serum 60 Xeloda ® 60 Zolinza 60 KRAS wild 60 breast carcinomas 60 metastatic adenocarcinoma 60 malignant ovarian 60 deCODE BreastCancer TM 60 concurrent chemoradiation 60 targeted radiotherapeutic 60 adjuvant radiation 60 diffuse gastric 60 beta carotene supplementation 60 oral antidiabetic medication 60 echocardiographic parameters 60 motesanib diphosphate 60 pemphigus vulgaris 60 Phase #b/#a clinical 60 specific antigen PSA 60 Chronic lymphocytic leukemia 60 Stereotactic body 60 subependymal giant cell 60 KRAS mutations 60 invasive ductal breast cancer 60 autologous transplants 59 Rituxan rituximab 59 pT3 59 cytologic examination 59 relapsed ovarian cancer 59 IgG1 monoclonal antibody 59 pancreatic endocrine 59 epithelial ovarian cancer 59 UVB induced 59 Quinamed 59 abnormal pap tests 59 gastrointestinal malignancies 59 Refractory Hodgkin Lymphoma 59 clinically localized prostate 59 neoadjuvant treatment 59 squamous cell carcinoma SCC 59 lobular breast cancer 59 EGFR mutation positive 59 cirrhosis liver failure 59 refractory Hodgkin 59 Amgen denosumab 59 HER2 ErbB2 59 Heavy menstrual bleeding 59 transfusion syndrome 59 neutropenic sepsis 59 TYMS 59 evaluating T DM1 59 ovarian colorectal 59 metastatic GIST 59 Ductal carcinoma 59 Oncotype DX ® 59 5 FU leucovorin 59 ductal lobular 59 myocardial infarction ventricular fibrillation 59 Vandetanib 59 minimally symptomatic 59 Tarceva TM 59 lintuzumab SGN 59 relapsed ALL 59 esophagus pancreas 59 refractory colorectal cancer 59 Stage IIIb 59 preoperative chemotherapy 59 #.#ng/ml 59 sitaxsentan 59 FOLFIRI alone 59 hormone refractory metastatic prostate 59 fibrate drugs 59 accumulate preferentially 59 hormone refractory prostate 59 Dendreon investigational 59 cytogenic 59 LymphoStat B TM 59 gastric pancreatic 59 metastatic castrate resistant 59 intraperitoneal therapy 59 liver metastasis 59 Intravenous immunoglobulin 59 esthesioneuroblastoma rare form 59 cervical colorectal 59 Neuvenge 59 MYCN amplification 59 forodesine 59 beta estradiol 59 Erbitux cetuximab 59 GlaxoSmithKline Tykerb 59 heFH 59 intestinal polyps 59 HER2 HER2 59 androgen independent 59 MAGE A3 protein 59 hyperplasia BPH 59 transarterial 59 peritoneal carcinomatosis 59 Raloxifene STAR 59 vitreous floaters 59 precancerous tissues 59 drug GAP #B# 59 ductal cancer 59 Modrenal 59 underwent radical prostatectomy 59 abnormal p# biomarker 59 pre eclamptic 59 XL# administered orally 59 gastrin analogue TT 59 androgen receptor antagonist 59 surgically resected 59 ribonucleotide reductase clinically validated 59 Evoltra ® 59 chronic myeloid 59 selective modulator 59 antiangiogenic therapy 59 colorectal bowel 59 neuroblastoma tumors 59 CIMZIA TM certolizumab pegol 59 Fludara ® 59 non splenectomized 59 trastuzumab Herceptin ® 59 pathological hallmark 59 castration resistant 59 ERalpha 59 chemopreventive agent 59 metastatic bone 59 anti angiogenic therapy 59 prostate carcinomas 59 localized prostate 59 acute leukemias 59 alvespimycin 59 Cimzia TM 59 hypereosinophilic syndrome 59 Gonal f R follitropin 59 HER2 receptor 59 IMA# 59 VEGF induced 59 malignant brain 59 EndoTAGTM 1 59 ZOLINZA 59 monoclonal antibody IgG1 Mab 59 alpha1 antitrypsin AAT deficiency 59 5 HT2A serotonin 59 Immunohistochemical staining 59 mitoxantrone plus 59 trastuzumab Herceptin R 59 oncogenic HPV 59 incontinence erectile dysfunction 59 STRIDE PD 59 epirubicin cyclophosphamide 59 SUVmax 59 BRAF V#E 59 fusion enhancers 59 Arranon 59 hepatocellular cancer 59 papillary carcinoma 59 Squamous 59 colon rectal 59 MKC# MT 59 nonmelanoma skin cancers 59 Colorectal cancer CRC 59 esophageal gastric 59 FLT3 ITD 59 dyskeratosis congenita 59 bladder cervix 59 anthracycline containing 59 androgen suppression therapy 59 pancreatic ductal 59 PCA3 gene 59 hepatic liver 59 novel VDA molecule 59 gastric adenocarcinoma 59 unresectable HCC 59 Adenocarcinoma 59 antiestrogen 59 GRN# 59 tryptase 59 advanced hepatocellular carcinoma 59 interferon beta therapy 59 esophagus colon 59 underwent radical cystectomy 59 pancreas colon 59 exemestane Aromasin 59 undergoing cardiac catheterization 59 gastric carcinoma 59 prostate cancer antigen prostatic 59 castrate resistant prostate cancer 59 elevated transaminases 59 plasma kallikrein inhibitor 59 Azacitidine 59 intraductal 59 renal carcinoma 59 metastatic lymph nodes 59 grade cervical intraepithelial 59 fibroids endometriosis 59 gastrointestinal stromal tumors 59 Myocet 59 ALN VSP Phase 59 Irinotecan 59 Improves Outcomes 59 5 Fluorouracil 59 invasive carcinomas 59 Bayer Nexavar 59 acyclovir Lauriad R 59 Renal cell carcinoma 59 fewer uterine cancers 59 HER2 neu 59 Glioblastoma Multiforme GBM 59 clinicopathological features 59 targeted nucleotide prodrug 59 orthotopic model 59 proprietary radiolabeled monoclonal 59 visit www.rtanswers.org 59 prostate pancreatic 59 Nat Rev 59 endocrine therapies 59 Hepatocellular Carcinoma HCC 59 PEGylated anti 59 irinotecan chemotherapy 59 pilocytic astrocytoma 59 extensively metabolized 59 asthma rheumatoid arthritis 59 vinflunine 59 pathologic diagnosis 59 candidemia 59 anastrozole Arimidex 59 estradiol gel indicated 59 TMPRSS2 ERG 59 lobular carcinoma 58 autologous SCT 58 Provectus Pharmaceuticals specializes 58 agonistic human 58 Patients Treated With 58 adjuvant hormonal therapy 58 dimensional conformal radiotherapy 58 androgen ablation 58 Pivotal Clinical Trial 58 mammographically 58 parathyroid carcinoma 58 distant metastasis 58 HuMax 58 treating sarcoma testicular 58 radical prostatectomy RP 58 oral ridaforolimus 58 cisplatin carboplatin 58 Completes Patient Enrollment 58 TMEM density 58 bone marrow reticulin deposition 58 MyVax R 58 colorectal neoplasms 58 gastrointestinal stromal tumor GIST 58 Neoadjuvant 58 anaplastic lymphoma kinase ALK 58 ER CHOP 58 leukemia lymphoma multiple myeloma 58 precancerous tumors 58 dacarbazine DTIC 58 RhuDex R 58 Homocysteine levels 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 postoperative chemotherapy 58 ORENCIA ® 58 Immunotherapeutic 58 interferon beta 1a infertility 58 Neulasta R 58 HER2 amplification 58 circulating endothelial cells 58 baseline neutrophil counts 58 docetaxel cisplatin 58 Zarnestra 58 systemic invasive fungal 58 SinuNase ™ 58 PremPro 58 radiolabeled TM# 58 metastatic liver 58 polyp recurrence 58 colorectal adenocarcinoma 58 intravenous bisphosphonates 58 J Am Coll 58 wrote Kaunitz 58 ToGA 58 atypia 58 ovarian esophageal 58 hematological cancers notably 58 Telik logo TELINTRA 58 ASCUS 58 Epithelial ovarian cancer 58 AAG geldanamycin analog 58 receiving INTRON 58 familial hypercholesterolemia FH 58 EGFr expressing metastatic colorectal 58 pituitary adenoma 58 allogeneic hematopoietic stem cell 58 Fibroblast 58 receptor tyrosine kinase inhibitor 58 Intravenous CP 58 abnormal pap smears 58 subcutaneous immunoglobulin 58 TOP2A 58 indolent follicular non 58 imatinib Gleevec 58 Gynecologic Oncology Group 58 paclitaxel Taxol 58 Allovectin 7 58 ano genital warts 58 farletuzumab 58 aMCI precursor 58 RRM1 58 cetuximab Erbitux R 58 squamous cell 58 radical retropubic prostatectomy 58 estrogen receptor negative 58 undergoing androgen deprivation 58 Bayer HealthCare Onyx Pharmaceuticals 58 aromatase inhibitor AI 58 #rd Annual CTRC 58 biologic DMARD 58 gynaecologic 58 Phase 2b Clinical Trial 58 intraoperative radiotherapy 58 CLL SLL 58 Factor Receptor 58 axillary node 58 ADPKD 58 erlotinib Tarceva 58 DCVax R 58 uterus womb 58 visceral metastases 58 sunitinib sorafenib 58 prostate colon 58 hemodynamically significant 58 CCyR 58 VALSTAR TM 58 deletion 5q 58 cytotoxic therapy 58 irreversible inhibitor 58 Upregulation 58 CR nPR 58 assessing T DM1 58 medullary thyroid 58 vinca alkaloid 58 OVATURE 58 axillary lymph nodes 58 hyperphenylalaninemia HPA due 58 G CSFs 58 catheter occlusion 58 C1 INH deficiency 58 recurrent glioblastoma multiforme GBM 58 samalizumab 58 proximal colon 58 midstage clinical 58 BRAF mutations 58 Parathyroid Hormone 58 potent suppressor 58 Lewy bodies DLB 58 dasatinib Sprycel ® 58 TRAIL R2 58 idiopathic PAH 58 chronic eosinophilic leukemia 58 mutated KRAS gene 58 leukemia lymphomas 58 LH FSH 58 gastrointestinal stromal tumors GIST 58 OvaRex MAb 58 OvaRex 58 axillary nodes 58 substantially excreted 58 Elevated PSA 58 testicular tumors 58 OncoVex 58 Phase #/#a trial 58 Antitumor Activity 58 CMV infections 58 orally administered inhibitor 58 artery embolization 58 HBeAg negative 58 biliary tract cancers 58 FLT3 mutations 58 benign uterine 58 Digital Mammographic Imaging 58 evaluating Actimmune 58 elevated LDH 58 deforolimus 58 postoperative radiotherapy 58 bronchoalveolar lavage fluid 58 Chlamydia trachomatis infection 58 gastrointestinal stromal tumor 58 pamidronate 58 extracapsular extension 58 IgM isotype 58 MALT lymphoma 58 retinal vein occlusion induced 58 Estrogen Receptor 58 perimenopausal women 58 adenomatous polyps 58 chronic rheumatic 58 hematological relapse 58 Fluorouracil 58 Personalized Immunotherapy 58 endostatin 58 Theratope 58 seminomas 58 generation PNP inhibitor 58 chronic granulomatous disease 58 lymph node metastases 58 OnDose TM 58 mutated p# 58 KRAS gene mutations 58 PhG alpha 1 58 Begins Dosing 58 endometrioid 58 pulmonary metastasis 58 Squamous Cell 58 oligodendrogliomas 58 imatinib Gleevec ® 58 TRAIL R1 58 transplantation HCT 58 baseline LDH 58 Hurthle cell 58 progressively degenerative 58 CIN3 58 treat secondary hyperparathyroidism 58 undergoing hematopoietic stem 58 estrogen progestin therapy 58 formerly LymphoStat B 58 SPRYCEL ® 58 underarm lymph nodes 58 Annamycin 58 dysplastic nevi 58 chronic thromboembolic pulmonary 58 T1a 58 NSABP B 58 topical gel containing 58 elderly myelodysplastic syndromes 58 colorectal polyp 58 abnormal Pap smear 58 Preclinical Study 58 MGUS 58 TroVax ® 58 Torisel temsirolimus 58 postoperative mortality 58 lactate dehydrogenase LDH 58 stage IIIB 58 Daclizumab 58 cyclophosphamide chemotherapy 58 idiopathic membranous nephropathy 58 Cianna Medical Inc. 58 leiomyoma 58 TTR gene 58 gestational hypertension 57 ALB # 57 sulfonylurea metformin 57 chemoradiotherapy 57 cervical carcinoma 57 hematological diseases 57 COPEGUS therapy 57 motesanib 57 iniparib 57 molecular subtypes 57 malignant pleural mesothelioma 57 SCIg 57 B7 H3 57 leukemia AML 57 neoadjuvant 57 Crohn colitis 57 lymph node metastasis 57 Vitaxin